AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01298219 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo, 0 mcg administered orally twice daily (BID)
Study NCT01537120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Study NCT01537120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT03803423 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Donor App
Description: The Donor app is a web-based application that helps transplant candidates tell the candidate's story via social media in the hopes of identifying an appropriate living donor. Sample stories created using the Donor App can be found at www.thedonorapp.com.
Study NCT02465944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FFP104
Description: Three intravenous infusions of FFP104 over 15 days (d0, d7 and d14)
Study NCT02465944 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three intravenous infusions of 0.9% Saline over 15 days (d0, d7 and d14)
Study NCT01581437 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: 64 pole basket catheter
Description: The 64 pole basket catheter expands into a small flexible balloon that conforms to the atrial anatomy.
Study NCT02257073 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment
Study NCT02257073 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Waiting List
Study NCT02691689 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Genetic testing
Description: Genetic testing by DNA sequencing on blood samples after DNA extraction
Study NCT02810366 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physician versus Computer Coded Verbal Autopsy
Description: Comparing the performance of computer coded verbal autopsies (CCVA) to physician coded verbal autopsies (PCVA) at the population level.
Study NCT02810366 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physician versus Computer Coded Verbal Autopsy
Description: Comparing the performance of computer coded verbal autopsies (CCVA) to physician coded verbal autopsies (PCVA) at the population level.
Study NCT02143505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ca plus vit D
Description: elemental calcium 1200mg/d plus vitamin D3 250 IU/d daily supplements
Study NCT02192996 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Probiotic
Description: blood and fecal samples were collected from five VLBW preterms which were supplemented with a probiotic mixture of Bifidobacterium breve / Lactobacillus salivarius isolated from human milk
Study NCT02262715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-787
Description: Participants will receive VX-787, 600 mg either two times a day or once a day in either of the Part.
Study NCT02262715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Participants will receive Oseltamivir 75 mg either two times a day or once a day in either of the Part.
Study NCT02262715 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo matching to VX-787 either two times a day or or once a day.
Study NCT00842023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nesiritide
Description: Bolus 2 mcg/kg followed by 0.01 mcg/kg/min
Study NCT00842023 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitroglycerin
Description: 5-10 mcg/min titrating per protocol based on blood pressure
Study NCT02431286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: aprepitant will be administered in preoperative period; intravenous palonosetron and dexamethasone will be administered intraoperatively
Study NCT02431286 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered in the preoperative period; intravenous palonosetron and dexamethasone will be administered intraoperatively
Study NCT02431286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone and plonosetron will be administered intraoperatively in both groups, durong surgery
Study NCT02431286 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone and plonosetron will be administered intraoperatively in both groups, durong surgery
Study NCT03242850 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: This group will view a video on shared reading upon enrollment, receive standard guidance on shared reading, and receive a series of text messages for a period of 6 months.
Study NCT04424043 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neo-TACE-HAIC+Surgery
Description: transartery chemoembolization with lipiodol and EADM, FOLFOX (Oxa 85mg/m2 2h+CF 400mg/m2 2h +5FU 400mg/m2 10min+5FU 1200mg/m2 23h)-based artery infusion chemotherapy, followed by hepatic resection
Study NCT04424043 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery alone
Description: hepatic resection remove the liver tumors
Study NCT01692041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ivy leaves dry extract
Description: 5 ml twice daily po
Study NCT01692041 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 ml per os twice daily
Study NCT03095326 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc
Description: formula of ZnSO4, usually used to treat zinc deficiency.
Study NCT03095326 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sucrose
Description: Placebo of sucrose syrup
Study NCT03095326 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PCV Vaccine
Description: Pneumococcal conjugate vaccine
Study NCT03095326 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV Vaccine
Description: Pneumococcal conjugate vaccine
Study NCT03095326 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PPV Vaccine
Description: Pneumococcal polysaccharide vaccine
Study NCT03907475 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT03907475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study NCT03907475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given IV
Study NCT03907475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT03907475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin Hydrochloride
Description: Given IV
Study NCT03914742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PARP Inhibitor BGB-290
Description: Given PO
Study NCT03914742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study NCT03914742 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: resection surgery
Study NCT02951091 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: biomarker screening
Description: immunohistochemistry and in situ hybridization
Study NCT02951091 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: biomarker screening
Description: immunohistochemistry and in situ hybridization
Study NCT04568538 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training program
Description: A training program and booklet content for the education to be given to mothers includes the following topics.~* What is shaken baby syndrome and what is its cause?~* What are the harms caused by shaken baby syndrome?~* How is shaken baby syndrome understood?~* What problems can shaken baby syndrome cause?~* What are the measures to be taken? For the training and the content of the booklet, expert opinion was obtained from 10 academic members who are experts in the field of Child Health. An evaluation form was created for pre-test and post-test measurements. Expert opinions were also received for these forms.~Mothers of 2-4 months old babies who applied to Akdeniz University Hospital Pediatric Outpatient Clinic for check-up were randomized with a sealed envelope and accepted the study. In this way, intervention and control groups can be determined. After the pre-test is done in the intervention group, 2-month training, booklet and tele-consultancy services will be provided.
Study NCT01510847 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Andriol Testocaps
Description: Oral, 40mg, Twice a day, 30days
Study NCT03151434 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: US Guided Single Shot Paravertebral Block (0.2% ropivicaine infusion)
Description: Single shot paravertebral block will be placed under ultrasound guidance at the thoracic region prior to surgery.
Study NCT03151434 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: US Guided Paravertebral Catheter (0.2% ropivicaine bolus)
Description: Paravertebral catheter will be placed under ultrasound guidance at the thoracic region prior to surgery.
Study NCT03151434 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic Epidural (0.125% bupivicaine/hydromorphone)
Description: Epidural catheter will be placed in the thoracic region prior to surgery.
Study NCT04019847 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STAK Tool
Description: Medical stretching device
Study NCT04019847 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard treatment
Description: Physiotherapists tailor treatment of arthrofibrosis to meet their patients' individual needs. Treatment may comprise the following: education, advice and a range of stretching exercises/techniques to change the length and density of the adhesions and shortened tissue. These include active range of movement (AROM), passive range of movement (PROM), strengthening exercises, hands-on high intensity passive physiological stretches, joint mobilisations and a home exercise programme involving full weight bearing exercises with the aim of enabling the patient to regain AROM and function
Study NCT04019847 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Physiotherapists tailor treatment of arthrofibrosis to meet their patients' individual needs. Treatment may comprise the following: education, advice and a range of stretching exercises/techniques to change the length and density of the adhesions and shortened tissue. These include active range of movement (AROM), passive range of movement (PROM), strengthening exercises, hands-on high intensity passive physiological stretches, joint mobilisations and a home exercise programme involving full weight bearing exercises with the aim of enabling the patient to regain AROM and function
Study NCT03057795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Given IV
Study NCT03095326 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PPV Vaccine
Description: Pneumococcal polysaccharide vaccine
Study NCT02752243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CIK-Cells
Description: IL-15 activated CIK cells individually generated from PB mononuclear cells of the original stem cell donors.
Study NCT01009450 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LC was done using traditional method
Description: LC was done using traditional method by dissection of calot's triangle and clipping of both cystic duct and artery by metal clips. Then dissection of gall bladder from its bed by hook using electrocautery technique. Finally we insert abdominal drain in Morrison pouch.
Study NCT01009450 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LC was done using harmonic ACE
Description: LC was done using harmonic ACE (Ethicon Endo-Surgery) by dissection of calot's and then occlusion of both cystic duct and artery using harmonic ACE. For closure of and division of cystic pedicle we set the instrument at a power 2 i.e. more coagulation. And when dissecting the gall bladder from the bed we set it to the level 5 i.e. more cutting power. And control of any bleeding from the bed using the active blade of harmonic ACE. Finally we insert abdominal drain in Morrison pouch.
Study NCT01920958 — intervention group
Intervention type: OTHER
Intervention: TachoSil®
Description: TachoSil® is a collagen sponge that is coated with the active substances human fibrinogen and human thrombin and that supports hemostasis and tissue sealing in surgery.
Study NCT02746965 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magpro X100 + Option
Description: In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of MST in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
Study NCT02746965 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ThymatronSystem Ⅳ Electroconvulsive System
Description: In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of modified ECT in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
Study NCT02746965 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: treatment as usual (TAU)
Description: Participants will engage in their inpatient treatment program as-usual.
Study NCT02746965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: treatment as usual (TAU)
Description: Participants will engage in their inpatient treatment program as-usual.
Study NCT03114930 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: To study the absence of increased complications and events occurring in the mother-newborn
Description: To study the absence of increased complications and events occurring in the mother-newborn couple who made a standard exit compared to the mother-newborn couples who had benefited from an extra day of  Hospitalization in maternity.
Study NCT04736498 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inferior venacava Ultrasonography (IVC USG) guided fluid management
Description: The IVC will be visualized using a paramedian long-axis view via a subcostal approach. A two-dimensional image of the IVC as it enters the right atrium will be first obtained. Variations in IVC diameter with respiration will be assessed using M-mode imaging performed 2 to 3 cm distal to the junction of right atrium and IVC. Maximum and minimum diameter will be measured from inner wall to inner wall and collapsibility index(CI) will be calculated using formula: CI = \[(dIVCmax - dIVCmin)/dIVCmax\] x 100% CI of ˃36% will be accepted as predicted fluid responder and ≤36% will be regarded as predicted fluid non responders. Predicted fluid responders will receive a bolus of 500 ml of Ringer's lactate over a time period of 15 min, after which the IVC diameter variation will be reassessed. Additional 250ml of Ringer's lactate bolus will be applied until a non fluid responder pattern is observed during IVC USG. Thereafter,spinal anaesthesia will be performed.
Study NCT03188289 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo gel
Description: Placebo is the control group treated with a placebo gel.
Study NCT03188289 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: Placebo is the control group treated with a placebo gel.
Study NCT03188289 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clorhexidine gel
Description: Clorhexidine will be compare with placebo, clorhexidine-chitosán and hyaluronic acid bioadhesive gels
Study NCT03188289 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clorhexidine gel
Description: Clorhexidine will be compare with placebo, clorhexidine-chitosán and hyaluronic acid bioadhesive gels
Study NCT03188289 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clorhexidine-Chitosan gel
Description: Clorhexidine-chitosan will be compare with placebo, clorhexidine and hyaluronic acid bioadhesive gels.
Study NCT03188289 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clorhexidine-Chitosan gel
Description: Clorhexidine-chitosan will be compare with placebo, clorhexidine and hyaluronic acid bioadhesive gels.
Study NCT03188289 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic Acid gel
Description: Hyaluronic acid will be compare with placebo, clorhexidine, clorhexidine-chitosan bioadhesive gels
Study NCT03188289 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hyaluronic Acid gel
Description: Hyaluronic acid will be compare with placebo, clorhexidine, clorhexidine-chitosan bioadhesive gels
Study NCT01789112 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Taking of blood sample
Study NCT01051596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 150mg/m2 Days 1-5 of each 28 day cycle
Study NCT01051596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-888
Description: 40mg orally BID Days 1-7 of each 28 day cycle
Study NCT02165917 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Excision plus hyaluronic acid gel
Description: Excision of endometriosis foci by laparoscopic standard methods followed by an application of 10 cc Hyaluronic acid gel, in order to prevent postsurgical adhesions.
Study NCT02165917 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Excision only
Description: Excision of endometriosis foci by laparoscopic standard methods only.
Study NCT04687839 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Induction of suction blister
Description: For each subject, 2 superficial wounds will be made on the inner aspect of each forearm using the suction blister model.
Study NCT04687839 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transepidermal water loss (TEWL)
Description: * At V1, before blister suction use (T0) and after blister withdrawal before product application (T1)~* For subsequent visits, before product application
Study NCT04687839 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Macrophotography
Description: * At V1, before blister suction use (T0) and after blister withdrawal before product application (T1)~* For subsequent visits, before product application
Study NCT04687839 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wound healing medical device
Description: Twice daily application on superficial wounds
Study NCT01031680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: 10 mg tablet, oral, once daily, 24- week treatment and 80-week extension period
Study NCT01031680 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablet, oral, once daily, 24- week treatment and 80-week extension period
Study NCT02063061 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham treatment
Description: Patients will receive simulated treatment, with the same ESWT unit as in other arm. Placebo gel-pad is design to prevent shockwaves emission. Looks identical as active gel-pad.
Study NCT02063061 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ESWT treatment
Description: ESWT treatment group will receive 600 low-energy, linear shockwaves against erectile dysfunction per week in 10 weeks.
Study NCT02063061 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: ESWT treatment
Description: ESWT treatment group will receive 600 low-energy, linear shockwaves against erectile dysfunction per week in 10 weeks.
Study NCT00383760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eribulin mesylate
Description: Given IV
Study NCT00602459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT00602459 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine Phosphate
Description: Given IV or PO
Study NCT00602459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV or PO
Study NCT00602459 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00602459 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00602459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study NCT00602459 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Given IV
Study NCT00602459 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT04073927 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sodium butyrate
Description: Sodium butyrate Class: Fatty acids Ingredients (100 g): Na-butyrate (50 g), acylglycerol (mono- di, -triacylglycerol; 42 g), bee wax (5 g), sodium alginate E401 (2 g), emulsifier (0.5 g).~The capsules contain granulated sodium butyrate and are coated with a sodium alginate membrane.
Study NCT04073927 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sodium butyrate
Description: Sodium butyrate Class: Fatty acids Ingredients (100 g): Na-butyrate (50 g), acylglycerol (mono- di, -triacylglycerol; 42 g), bee wax (5 g), sodium alginate E401 (2 g), emulsifier (0.5 g).~The capsules contain granulated sodium butyrate and are coated with a sodium alginate membrane.